Inflammatory Bowel Disease (IBD) Market Anticipates Impressive Growth Trajectory Through 2032 – Asserts DelveInsight | Takeda, AstraZeneca, Janssen, Abbvie, Eli Lilly, Gilead, Galapagos

Inflammatory Bowel Disease (IBD) Market Anticipates Impressive Growth Trajectory Through 2032 - Asserts DelveInsight | Takeda, AstraZeneca, Janssen, Abbvie, Eli Lilly, Gilead, Galapagos
Delveinsight Business Research LLP
As per DelveInsight, the Inflammatory Bowel Disease therapeutics market is anticipated to evolve immensely in the coming years owing to the expected launch of investigational drugs and the rise in the number of cases of Inflammatory Bowel Disease.

DelveInsight’s “Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Inflammatory Bowel Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Inflammatory Bowel Disease drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Inflammatory Bowel Disease treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Inflammatory Bowel Disease: An Overview

Inflammatory Bowel Disease (IBD) is a complex chronic disease resulting from the dysregulation of the immune system triggered by genetic, epigenetic, microbial, and environmental factors. Ulcerative colitis (UC) and Crohn’s disease (CD) are two forms of inflammatory bowel disease that can cause serious and debilitating symptoms and disruptions in daily life.

Ulcerative colitis occurs when the immune system sends white blood cells into the lining of the intestines, where they produce chronic inflammation and ulcerations. There is an unmet need for additional treatment options for Ulcerative colitis that provide meaningful symptom relief, including bowel urgency, and deliver sustained clinical remission. Crohn’s disease is a chronic immune-mediated condition of the gastrointestinal (GI) tract. Crohn’s most commonly affects the end of the small bowel (the ileum) and the beginning of the colon, but it may affect any part of the GI tract, from the mouth to the anus. Inflammatory Bowel Disease, including Crohn’s disease and Ulcerative colitis, affects approximately 10 million people worldwide.

Inflammatory Bowel Disease Market Key Facts

  • In the 7MM, there were ~3,835,000 prevalent cases of Inflammatory Bowel Disease in total during the year 2021. This count is anticipated to increase during the forecast period over all the geographies.

  • In the EU-5 region, there were ~634,000 and ~1,021,000 prevalent cases of Crohn’s disease and Ulcerative colitis, respectively, in 2021.

  • In 2021, in Germany, there were ~357,000 prevalent cases of Ulcerative Colitis (UC), and ~227,000 cases were recorded for Crohn’s disease (CD).

  • Japan accounted for ~331,000 prevalent cases of Inflammatory Bowel Disease in 2021, which makes up around 9% of the total Inflammatory Bowel Disease cases in the 7MM. Out of all the prevalent cases in Japan, there were around 72% diagnosed with prevalent cases of Inflammatory Bowel Disease in 2021.

  • The pipeline for Inflammatory Bowel Disease is currently lucrative, consisting of many key assets in the late stage of development. Some of the most promising emerging therapies in the pipeline include Mirikizumab, Filgotinib, and others. Major pharma and biotech giants such as Takeda, Eli Lilly, Gilead, AstraZeneca, and others are actively working in the Inflammatory Bowel Disease therapeutics market.


Inflammatory Bowel Disease Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Inflammatory Bowel Disease pipeline therapies. It also thoroughly assesses the Inflammatory Bowel Disease market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Inflammatory Bowel Disease drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Inflammatory Bowel Disease Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Inflammatory Bowel Disease epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Inflammatory Bowel Disease epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Inflammatory Bowel Disease Epidemiology, Segmented as –

  • Number of Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in the 7MM [2019–2032]

  • Number of Prevalent Cases of Inflammatory Bowel Disease (IBD) in the 7MM [2019–2032]

  • Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in the 7MM [2019–2032]

  • Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in the 7MM [2019–2032]

  • Type-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in the 7MM [2019–2032]

  • Gender-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in the 7MM [2019–2032]

Inflammatory Bowel Disease Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Inflammatory Bowel Disease market or expected to be launched during the study period. The analysis covers the Inflammatory Bowel Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Inflammatory Bowel Disease drugs based on their sale and market share.

The report also covers the Inflammatory Bowel Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Inflammatory Bowel Disease companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Inflammatory Bowel Disease Market Will Evolve and Grow by 2032 @

Inflammatory Bowel Disease Therapeutics Analysis

The goal of inflammatory bowel disease treatment is to reduce the inflammation that triggers your signs and symptoms. In the best cases, this may lead not only to symptom relief but also to long-term remission and reduced risks of complications. Inflammatory Bowel Disease treatment usually involves either drug therapy or surgery. Anti-inflammatory drugs are the first step in Inflammatory Bowel Disease treatment. These drugs help decrease inflammation of the digestive tract. However, they have many side effects.

Glucocorticoids, a subcategory of corticosteroids, are examples of anti-inflammatory drugs used for IBD. They include budesonide (Uceris), prednisone (Prednisone Intensol, Rayos), prednisolone (Millipred, Prelone), and methylprednisolone (Medrol, Depo-Medrol). These drugs are available in a variety of forms, from oral tablets to injections to rectal foams. They are usually given at the lowest dose possible for the shortest amounts of time.

5-ASA drugs (aminosalicylates) also decrease inflammation, mainly in the last part of the small intestine and in the colon. They include balsalazide (Colazal), mesalamine (Apriso, Asacol HD, Canasa, Pentasa), olsalazine (Dipentum), which is only available as a brand-name drug, sulfasalazine (Azulfidine). 

In 2019, the American Gastroenterological Association (AGA) strongly recommended: standard-dose oral mesalamine, and diazo-bonded 5-ASA drugs, such as balsalazide, and olsalazine They are preferred over low-dose mesalamine, sulfasalazine, or no treatment.

Inflammatory Bowel Disease Companies Actively Working in the Therapeutics Market Include

  • Takeda

  • AstraZeneca

  • Janssen Pharmaceuticals

  • Abbvie

  • Eli Lilly and Company

  • Applied Molecular Transport

  • Gilead

  • Galapagos

And Many Others

Emerging and Marketed Inflammatory Bowel Disease Therapies Covered in the Report Include:

  • Stelara (ustekinumab): Janssen Pharmaceuticals

  • Humira (adalimumab): Abbvie

  • Mirikizumab: Eli Lilly and Company

  • AMT-101: Applied Molecular Transport

  • Tremfya (guselkumab): Janssen

  • JYSELECA (filgotinib): Gilead/Galapagos

And Many More 

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Inflammatory Bowel Disease Competitive Intelligence Analysis

4. Inflammatory Bowel Disease Market Overview at a Glance

5. Inflammatory Bowel Disease Disease Background and Overview

6. Inflammatory Bowel Disease Patient Journey

7. Inflammatory Bowel Disease Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Inflammatory Bowel Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Inflammatory Bowel Disease Unmet Needs

10. Key Endpoints of Inflammatory Bowel Disease Treatment

11. Inflammatory Bowel Disease Marketed Therapies

12. Inflammatory Bowel Disease Emerging Drugs and Latest Therapeutic Advances

13. Inflammatory Bowel Disease Seven Major Market Analysis

14. Attribute Analysis

15. Inflammatory Bowel Disease Market Outlook (In US, EU5, and Japan)

16. Inflammatory Bowel Disease Companies Active in the Market

17. Inflammatory Bowel Disease Access and Reimbursement Overview

18. KOL Views on the Inflammatory Bowel Disease Market

19. Inflammatory Bowel Disease Market Drivers

20. Inflammatory Bowel Disease Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Hemostats Market

The global Hemostats market was valued at USD 3.64 billion in 2021, growing at a CAGR of 5.72% during the forecast period from 2023 to 2028 to reach USD 5.07 billion by 2028. The Hemostats market is slated to witness prosperity owing to factors such as the increasing number of surgical procedures, the growing focus on blood loss management during surgeries, emphasis on improving the safety and usability of hemostats for end users along with technological advancements are expected to result in appreciable revenue growth in the hemostats market during the forecast period (2023-2028). Some of the key market players operating in the hemostats market include Baxter International Inc., Johnson and Johnson, GELITA Medical, B. Braun Melsungen AG, Hemostasis LLC, Stryker Corporation, Pfizer, Mallinckrodt, CryoLife, and others.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States